X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
(CIPL)
Here is the latest financial fact sheet of Cipla. For more details, see the Cipla quarterly results and Cipla share price and chart. For a sector overview, read our pharmaceuticals sector report.
| % ch | % | 0.4 |
| No. of shares | m | 804.21 |
| % ch week | % | -1.5 |
| % ch 1-mth | % | -3.5 |
| % ch 12-mth | % | 11.9 |
| 52 week H/L | Rs | 621.9/460.0 |
| No. of Mths Year Ending |
12 Mar-12* |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
5-Yr Chart Click to enlarge
|
|---|
| CIPLA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 359 | 435 | 450 | 753 | 748 | |
| Low | Rs | 274 | 301 | 364 | 369 | 495 | |
| Sales per share (Unadj.) | Rs | 87.4 | 103.1 | 126.7 | 141.3 | 170.3 | |
| Earnings per share (Unadj.) | Rs | 14.3 | 19.2 | 17.3 | 14.7 | 18.7 | |
| Diluted earnings per share | Rs | 14.2 | 19.2 | 17.3 | 14.7 | 18.7 | |
| Cash flow per share (Unadj.) | Rs | 18.1 | 23.4 | 21.9 | 21.0 | 25.5 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Adj. dividends per share | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Dividend yield (eoy) | % | 0.6 | 0.5 | 0.5 | 0.4 | 0.3 | |
| Book value per share (Unadj.) | Rs | 95.1 | 112.3 | 125.2 | 134.5 | 147.6 | |
| Adj. book value per share | Rs | 95.0 | 112.1 | 125.0 | 134.3 | 147.4 | |
| Shares outstanding (eoy) | m | 802.92 | 802.92 | 802.92 | 802.96 | 803.38 | |
| Bonus/Rights/Conversions | - | - | - | ESOP | ESOP | ||
| Price / Sales ratio | x | 3.6 | 3.6 | 3.2 | 4.0 | 3.7 | |
| Avg P/E ratio | x | 22.2 | 19.1 | 23.5 | 38.1 | 33.2 | |
| P/CF ratio (eoy) | x | 17.4 | 15.8 | 18.6 | 26.7 | 24.4 | |
| Price / Book Value ratio | x | 3.3 | 3.3 | 3.3 | 4.2 | 4.2 | |
| Dividend payout | % | 14.0 | 10.4 | 11.6 | 13.6 | 10.7 | |
| Avg Mkt Cap | Rs m | 254,124 | 295,475 | 326,829 | 450,139 | 499,381 | |
| No. of employees | `000 | NA | NA | NA | NA | 24.1 | |
| Total wages/salary | Rs m | 7,725 | 10,360 | 15,430 | 19,737 | 24,471 | |
| Avg. sales/employee | Rs Th | NM | NM | NM | NM | 5,677.3 | |
| Avg. wages/employee | Rs Th | NM | NM | NM | NM | 1,015.7 | |
| Avg. net profit/employee | Rs Th | NM | NM | NM | NM | 625.0 | |
| CIPLA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 70,207 | 82,793 | 101,734 | 113,454 | 136,783 | |
| Other income | Rs m | 1,395 | 2,221 | 2,654 | 1,656 | 2,089 | |
| Total revenues | Rs m | 71,602 | 85,015 | 104,388 | 115,110 | 138,872 | |
| Gross profit | Rs m | 16,618 | 21,979 | 21,331 | 21,617 | 25,011 | |
| Depreciation | Rs m | 3,122 | 3,305 | 3,726 | 5,047 | 5,417 | |
| Interest | Rs m | 383 | 339 | 1,457 | 1,683 | 1,613 | |
| Profit before tax | Rs m | 14,508 | 20,556 | 18,800 | 16,543 | 20,070 | |
| Minority Interest | Rs m | 0 | 0 | -159 | -482 | -494 | |
| Prior Period Items | Rs m | 0 | -62 | -123 | -253 | -120 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 398 | 0 | 0 | 0 | |
| Tax | Rs m | 3,065 | 5,443 | 4,634 | 4,000 | 4,396 | |
| Profit after tax | Rs m | 11,442 | 15,449 | 13,884 | 11,808 | 15,059 | |
| Gross profit margin | % | 23.7 | 26.5 | 21.0 | 19.1 | 18.3 | |
| Effective tax rate | % | 21.1 | 26.5 | 24.6 | 24.2 | 21.9 | |
| Net profit margin | % | 16.3 | 18.7 | 13.6 | 10.4 | 11.0 | |
| CIPLA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 50,568 | 67,840 | 56,514 | 75,914 | 88,422 | |
| Current liabilities | Rs m | 14,132 | 22,776 | 25,636 | 38,936 | 79,089 | |
| Net working cap to sales | % | 51.9 | 54.4 | 30.4 | 32.6 | 6.8 | |
| Current ratio | x | 3.6 | 3.0 | 2.2 | 1.9 | 1.1 | |
| Inventory Days | Days | 96 | 105 | 104 | 122 | 102 | |
| Debtors Days | Days | 81 | 74 | 59 | 64 | 63 | |
| Net fixed assets | Rs m | 35,867 | 39,878 | 44,452 | 48,521 | 110,786 | |
| Share capital | Rs m | 1,606 | 1,606 | 1,606 | 1,606 | 1,607 | |
| "Free" reserves | Rs m | 74,248 | 87,818 | 98,591 | 105,484 | 115,989 | |
| Net worth | Rs m | 76,389 | 90,187 | 100,504 | 108,015 | 118,574 | |
| Long term debt | Rs m | 33 | 6 | 3,179 | 3,093 | 2,219 | |
| Total assets | Rs m | 93,498 | 116,588 | 134,032 | 157,175 | 208,926 | |
| Interest coverage | x | 38.8 | 61.6 | 13.9 | 10.8 | 13.4 | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.8 | 0.7 | 0.8 | 0.7 | 0.7 | |
| Return on assets | % | 12.6 | 13.5 | 11.4 | 8.6 | 8.0 | |
| Return on equity | % | 15.0 | 17.1 | 13.8 | 10.9 | 12.7 | |
| Return on capital | % | 19.5 | 23.5 | 19.3 | 15.7 | 17.4 | |
| Exports to sales | % | 52.6 | 53.5 | 48.6 | 41.7 | 48.9 | |
| Imports to sales | % | 16.1 | 15.9 | 14.0 | 14.7 | 12.6 | |
| Exports (fob) | Rs m | 36,920 | 44,262 | 49,480 | 47,363 | 66,837 | |
| Imports (cif) | Rs m | 11,333 | 13,162 | 14,261 | 16,629 | 17,270 | |
| Fx inflow | Rs m | 37,282 | 44,947 | 51,499 | 49,104 | 67,461 | |
| Fx outflow | Rs m | 13,292 | 15,906 | 18,943 | 22,483 | 24,729 | |
| Net fx | Rs m | 23,990 | 29,042 | 32,556 | 26,621 | 42,733 | |
| CIPLA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 17,128 | 13,977 | 15,633 | 11,734 | 17,939 | |
| From Investments | Rs m | -9,651 | -20,629 | -12,499 | -9,412 | -45,795 | |
| From Financial Activity | Rs m | -7,532 | 7,178 | -2,656 | 1,648 | 31,027 | |
| Net Cashflow | Rs m | -55 | 526 | 478 | 3,971 | 3,171 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Y. K. Hamied (MD) | COMP SEC: Mital Sanghvi | YEAR OF INC: 1935 | BSE CODE: 500087 | FV (Rs): 2 | DIV YIELD (%): 0.4 |
More Pharmaceuticals Company Fact Sheets: UNICHEM LAB SUN PHARMA NATCO PHARMA AJANTA PHARMA STRIDES SHASUN LTD
Compare CIPLA With: UNICHEM LAB SUN PHARMA NATCO PHARMA AJANTA PHARMA STRIDES SHASUN LTD
Compare CIPLA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Profit booking continued in the afternoon session in the Indian share markets amid weak European cues. At the closing bell, the BSE Sensex stood lower by 153 points.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
US markets decline while other geographies grow in the quarter.
Currency fluctuation and one time provision impacts operating margins.
Base price erosion in the US and lower Zetia sales impacts profits.
More Views on NewsWhich brings us back to the basic question, why was demonetisation carried out?
Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?
Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.
Trading is not synonymous with mutual funds, PersonalFN explains.
RBI and government at loggerheads over interest rates.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
